Eric Y. Chuang

Vice President,
​General Director, Biomedical Technology and Device Research Laboratories,
ITRI

​​​​
​

Eric Y. Chuang received his doctorate in cancer biology with toxicology and molecular genetics as
two sub-specialties from Harvard University in 1997 and his doctoral thesis was to study
radiation-induced mutagenesis in human cells. After graduation, he stayed at Harvard as a
postdoctoral fellow for one year. He then joined the Radiation Biology Branch of National Cancer
Institute (NCI), National Institutes of Health (NIH) as an IRTA fellow to study radiogenomics in
Bethesda, MD, USA. Next, he became the Head of Microarray Laboratory for Radiation Oncology
Sciences Program at NCI; his lab was to develop new initiatives that utilized state-of-the-art
microarray technologies for studying radiation oncology related research projects. After working
at the NIH for several years, he took a faculty position at National Taiwan University (NTU). In
2009, he joined the Radiation Research Program of Division of Cancer Treatment and Diagnosis
at NCI as a Program Director to oversee a portfolio of NIH grants that included radiation-induced
signaling pathways, molecular mechanisms and normal tissue injuries as well as radiation related
genomic studies. In 2011, he returned to NTU and was serving as the Director of Graduate
Institute of Biomedical Electronics and Bioinformatics (BEBI) in 2012-2018.
Dr. Chuang received his Executive MBA degree in International Business Management from NTU
in June 2017. Currently, he is a Professor of BEBI at NTU and serving as the Vice President and
General Director of the Biomedical Technology and Device Research Laboratories (BDL) at
Industrial Technology Research Institute (ITRI) in Hsinchu, Taiwan.
Being an expert in genomic technologies, bioinformatics, cancer, radiation biology & oncology,
biomedical engineering, and precision medicine, he has published more than 165 peer-reviewed
papers in related fields. Moreover, Dr. Chuang has been serving as an editorial board member of
Scientific Reports and the Editor-in-Chief of Translation Cancer Research.

Speech title & Synopsis

Opening Remarks & Panel Discussion

Moderator